anti-doping analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-08. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Gutter oil in other countries === Gutter oil has also been used outside of China as well, albeit not for human consumption. For example, in England, fatbergs that were dug out of sewers in cities like London and Liverpool were later reported to be processed to produce biofuel.
=== Fructose metabolism === Fructose must undergo certain extra steps in order to enter the glycolysis pathway. Enzymes located in certain tissues can add a phosphate group to fructose. This phosphorylation creates fructose-6-phosphate, an intermediate in the glycolysis pathway that can be broken down directly in those tissues. This pathway occurs in the muscles, adipose tissue, and kidney. In the liver, enzymes produce fructose-1-phosphate, which enters the glycolysis pathway and is later cleaved into glyceraldehyde and dihydroxyacetone phosphate.
As a legacy of SVB's Boston Private acquisition, it provided free banking services to many nonprofits in San Mateo County, California, who have needed to redirect donations to alternative bank accounts. Ahmad Thomas, CEO of the Silicon Valley Leadership Group, of which the bank was a member, described the failure as a setback for the San Francisco Bay Area's startup ecosystem and noted that it would be difficult to replicate the bank's business model.
== Development == In early embryogenesis, the esophagus develops from the endodermal primitive gut tube. The ventral part of the embryo abuts the yolk sac. It is very small in the beginning, but it lengthens due to descent of lungs and heart. During the second week of embryological development, as the embryo grows, it begins to surround parts of the sac. The enveloped portions form the basis for the adult gastrointestinal tract. The sac is surrounded by a network of vitelline arteries. Over time, these arteries consolidate into the three main arteries that supply the developing gastrointestinal tract: the celiac artery, superior mesenteric artery, and inferior mesenteric artery. The areas supplied by these arteries are used to define the midgut, hindgut and foregut. The surrounded sac becomes the primitive gut. Sections of this gut begin to differentiate into the organs of the gastrointestinal tract, such as the esophagus, stomach, and intestines. The esophagus develops as part of the foregut tube. The esophagus develops as a tube, lined with smooth muscle but continues development craniocaudally into different proportions of striated muscle. Both types of muscle have been demonstrated to be of different precursor cells. The innervation of the esophagus develops from the pharyngeal arches.
Sources: en.wikipedia.org
==== Astrocytes and blood oxygen levels ==== The Sur lab has discovered novel and critical roles for astrocytes in brain function. By high resolution imaging in the intact visual cortex, they showed that astrocytes have tuned calcium responses to visual stimuli that are mediated importantly via glutamate transporters on astrocyte processes that surround synapses, and they influence local blood flow and hence the hemodynamic signals that underlie brain imaging methods such as fMRI. Role of astrocytes in information processing and plasticity Astrocytes are also activated by neuromodulators such as acetylcholine and norepinephrine, and Sur and coworkers showed that cholinergic inputs to cortex act via astrocytes to alter the strength of excitatory synapses and implement plasticity of neuronal responses. Furthermore, astrocyte GABA transporters regulate extrasynaptic GABA and influence population coding of visual information by V1 neurons. Astrocyte calcium signaling influences excitatory drive to inhibitory neurons, thereby enabling astrocytes to modulate excitatory-inhibitory balance in neuronal V1 circuits. Astrocytes and learning Glutamate transporters on astrocytes regulate developmental plasticity in visual cortex. Gene expression (of glutamate and GABA transporters) in cortical astrocytes is modulated by learning, and astrocytes thus crucially shape cortical neuronal activity underlying learned behavior.
==== Clinical trials ==== In terms of antimicrobial performance, studies report that the peptides found in DBHA can selectively kill microorganisms without significant toxicity to host cells. This is attributed to the presence of free protonated amines in G3KPCA, which interact with and disrupt negatively charged bacterial membranes, contributing to bactericidal activity. In vitro compatibility tests using mouse NIH-3T3 fibroblasts showed that DBHA is non-cytotoxic under the tested condition. DBHA has also been tested in more realistic conditions, including bleeding environments. When applied to porcine skin covered in blood, only minor differences were observed between wet and dry adhesion performance. It was also tested on tissues such as the stomach, heart, artery, and liver, where adhesion forces were measured. In rat incision models, DBHA was used in wound closure studies where closure was observed after seven days, in comparison to conventional sutures and commercial adhesives. Additional testing showed that after 24 hours in an adhesive conditioned medium, human dermal fibroblasts remained viable, indicating biocompatibility.
Graham Stuart, MP for Beverley and Holderness, resigns from his ministerial post of Energy Minister with the UK government to spend more time focusing on local issues. He is replaced by Justin Tomlinson. Bambos Charalambous, MP for Enfield Southgate, is readmitted to the Labour Party following a ten month long internal investigation. 13 April – Tim Loughton, MP for East Worthing and Shoreham since 1997, announces he will stand down from parliament at the next election. He becomes the 100th MP to announce they will not seek re-election at the next election. An OpenDemocracy investigation reveals high level Labour politicians met with financial services firms following a £150,000 donation to the party from one of the companies. Simon Geraghty, the former leader of Worcester City Council, announces he will stand down at the May election after 24 years. Leader of Norfolk County Council Kay Mason Billig says that Natural England is blocking the proposed Norwich Northern Distributor Road scheme by protecting a bat colony. Mayor of London Sadiq Khan launches what he describes as a "new climate action plan" for London, which includes a Net Zero Schools target and recommitting to making London Net Zero by 2030. 14 April – Some Conservative MPs and businesspeople are proposing to boycott Downing Street's Eid celebration, scheduled for the following day, because of the UK government's support for Israel. 15 April – Peers living outside London become eligible to claim £100 for accommodation expenses when they attend sittings at the House of Lords.
Adenylyl-sulfate reductase (glutathione) (EC 1.8.4.9) is an enzyme that catalyzes the chemical reaction AMP + sulfite + glutathione disulfide ⇌ {\displaystyle \rightleftharpoons } adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.
== Works cited == "The Best of 2004; The 14th Annual Computer Games Awards". Computer Games Magazine. No. 172. Fort Lauderdale, Florida: theGlobe.com. March 2005. pp. 48–56. "2004 Games of the Year". Computer Gaming World. No. 249. Cambridge, Massachusetts: Ziff Davis. March 2005. pp. 56–67. Retrieved November 3, 2020. Osborn, Chuck (2003). "Cover Story: Bloodlines - The Half Life 2 Engine Gets Dead Sexy". PC Gamer US. Vol. 10, no. 114. United States: Ace St. Germain. pp. 46–54. ISSN 1080-4471. Osborn, Chuck (2005). "Reviews - Vampire: The Masquerade - Bloodlines". PC Gamer US. Vol. 12, no. 132. United States: Ace St. Germain. pp. 92–94. ISSN 1080-4471.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.